UK pharmaceutical outsourcing specialist Quay Pharma is investing more than £2.5m in a move to a new factory and headquarters, which will allow it to increase its development and clinical trial manufacturing capacities. The move is also expected to create around 52 jobs over the next three years.
The new facility in North Wales, close to Quay Pharma's existing premises in the Wirral, brings together all of the company's services - currently housed in two separate facilities - under one roof. The 3,750m2 building, which is four times the size of the existing premises, will enable the company to meet increasing demand for its specialist capabilities including formulation development, novel drug delivery design, analytical method development and clinical trial manufacture and packaging.
There will also be opportunity to develop Quay Pharma's expertise in oral dosage form design and development, especially for new chemical entities that exhibit poor solubility and bio-availability.
"By creating this new advanced facility to our specific requirements, we will be able to offer an enhanced level of support to our clients," said Quay Pharma's ceo Mike Rubinstein.
Quay Pharma anticipates moving into the new facility, part-funded by the Welsh authority Government, in phases from January 2010.
The company is MHRA licensed and FDA registered.